Crossmark

Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis

Crossref DOI link: https://doi.org/10.1186/s40959-021-00128-5

Published Online: 2022-03-17

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, Jiandong

Lee, Sharen

Lakhani, Ishan

Yang, Lei

Liu, Tong

Zhang, Yuhui

Xia, Yunlong

Wong, Wing Tak

Bao, Kelvin King Hei

Wong, Ian Chi Kei

Tse, Gary https://orcid.org/0000-0001-5510-1253
Zhang, Qingpeng
License Information

Text and Data Mining valid from 2022-03-17

Version of Record valid from 2022-03-17
More Information

Article History

Received: 19 August 2021

Accepted: 20 December 2021

First Online: 17 March 2022

Declarations

:

: This study was approved by The Joint Chinese University of Hong Kong - New Territories East Cluster Clinical Research Ethics Committee.

: The need for informed consent was waived by the Ethics Committee owing to the retrospective and observational nature of the study.

: N/A.

: None.

Document is current

Any future updates will be listed below